Essa Pharma’s sole clinical-stage candidate was on track to fall short against Xtandi in a phase 2 prostate cancer trial, leading the biotech to terminate the study, abandon the candidate and ...

I had friends from various communities and met them on a daily basis,” Ruto’s co-lead Counsel Essa Faal quoted the witness’s initial statement. But the witness maintained that when he first ...

Antoinette Essa joined the CBS 6 family in September of 2009, as a reporter for the “A-List”, a segment featuring events in and around Central Virginia. In addition, she does daily blogs for ...

(RTTNews) - ESSA Pharma Inc. (EPIX) announced that it has made the decision to terminate the Phase 2 clinical trial evaluating in a 2:1 randomization masofaniten combined with enzalutamide versus ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

ESSA Pharma (NASDAQ:EPIX) plummeted about 70% premarket on Friday after ending its Phase 2 trial for a prostate cancer treatment. The trial tested masofaniten with enzalutamide versus enzalutamide ...

Mo Faal opened his goal account for Wrexham in style on Tuesday night, hitting a spectacular volley to round off a 3-0 EFL Trophy win against Wolverhampton Wanderers Under-21s. The 21-year-old ...

Prof. Gibril Faal is a multi-disciplinary business and development executive, and visiting professor in practice at the Firoz Lalji Institute for Africa (FLIA), London School of Economics (LSE). He is ...

Investing.com -- ESSA Pharma (NASDAQ:EPIX), a biotechnology company focused on developing treatments for metastatic castration-resistant prostate cancer, saw its stock downgraded by major ...